Human Immunodeficiency Virus Vaccine Trials

Robert J. O’Connell1,3, Jerome H. Kim1,3, Lawrence Corey2,3, and Nelson L. Michael1,3

1U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910
2Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024
Correspondence: nmichael@hivresearch.org

More than 2 million AIDS-related deaths occurred globally in 2008, and more than 33 million people are living with HIV/AIDS. Despite promising advances in prevention, an estimated 2.7 million new HIV infections occurred in that year, so that for every two patients placed on combination antiretroviral treatment, five people became infected. The pandemic poses a formidable challenge to the development, progress, and stability of global society 30 years after it was recognized. Experimental preventive HIV-1 vaccines have been administered to more than 44,000 human volunteers in more than 187 separate trials since 1987. Only five candidate vaccine strategies have been advanced to efficacy testing. The recombinant glycoprotein (rgp)120 subunit vaccines, AIDSvAX B/B and AIDSvAX B/E, and the Merck Adenovirus serotype (Ad)5 viral-vector expressing HIV-1 Gag, Pol, and Nef failed to show a reduction in infection rate or lowering of postinfection viral set point. Most recently, a phase III trial that tested a heterologous prime-boost vaccine combination of ALVAC-HIV vCP1521 and bivalent rgp120 (AIDSVAX B/E) showed 31% efficacy in protection from infection among community-risk Thai participants. A fifth efficacy trial testing a DNA/recombinant(r) Ad5 prime-boost combination is currently under way. We review the clinical trials of HIV vaccines that have provided insight into human immunogenicity or efficacy in preventing HIV-1 infection.

CHALLENGES FOR HIV-1 VACCINES

Several factors make development of a vaccine protective against HIV-1 infection a formidable scientific and technological challenge (Douek et al. 2006; Barouch 2008). Extraordinary viral diversity is perhaps the most intractable obstacle to vaccine development. Envelope amino acid sequence diversity among the nine subtypes (A, B, C, D, F, G, H, J, and K) and more than 35 circulating recombinant forms can vary up to 20% within a particular subtype and 35% between subtypes (Walker and Korber 2001; Gaschen et al. 2002). Extremely rapid and error-prone replication yields a large number of mutant genomes, some of which are able to escape immune control (Richman et al. 2003; Goulder and Watkins 2004; Mascola and Montefiori 2010). Another major obstacle is the lack of clear immune correlates of protection in humans (Pantaleo and Koup 2004; Plotkin 2008). As natural immune responses...
against HIV fail to prevent infection or eradicate the virus, HIV-1 vaccine development cannot emulate the disease-free immune state. Candidate vaccine immunogenicity can be characterized, but these responses cannot be rationally weighted for further evaluation in the absence of correlates of protection. Broadly neutralizing antibodies (NAb) do occur rarely in HIV-1-infected individuals (Simek et al. 2009; Zhou et al. 2010), and passive administration of high doses of monoclonal antibodies affords protection to simian human immunodeficiency virus (SHIV) infection in nonhuman primates (Baba et al. 2000; Mascola et al. 2000; Hessel et al. 2010). However, immunogens that elicit such antibodies have been elusive for many reasons including tolerance control and immunoregulation (Johnson and Desrosiers 2002; Haynes et al. 2005), sequestration of the epitope in the lipid membrane (Sun et al. 2008), and exposure of epitopes only transiently during viral entry (Frey et al. 2008). Cell mediated immunity also develops in most infected individuals in the form of cytotoxic T-lymphocyte (CTL) cell activity which suppresses HIV replication and produces β-chemokines but fails to eradicate infection (Cocchi et al. 1995; D’Souza and Harden 1996; Mackewicz et al. 1996). Finally, long-lived latent tissue reservoirs are established very early in infection, greatly complicating eradication of infection (Chun et al. 1997, 1998).

GENERAL APPROACHES TO VACCINE DEVELOPMENT

Prophylactic vaccines against HIV-1 have attempted to accomplish one of two goals: prevent establishment of infection through generation of NAb, or generation of T-cell responses that result in attenuation of pathogenesis once infection occurs (Douek et al. 2006; McMichael 2006). The latter approach has been referred to as “T-cell” vaccination (Korber et al. 2009). Whole inactivated HIV-1 vaccines (WIVs) have not been seriously considered for human vaccination largely owing to concerns that inactivation might be incomplete, especially when viral aggregates occur. Additional complicating factors include a loss of antigenicity seen with conventional virus inactivation strategies, relatively modest neutralization induced by WIVs using alternative inactivated approaches (Poon et al. 2005), and marginal protective efficacy in rhesus macaques (Lifson et al. 2004). Although live simian immunodeficiency virus (SIV) vaccine attenuated by deletion of the nef gene has shown protection against SIV infection (Daniel et al. 1992; Joag et al. 1998; Wyand et al. 1999), safety concerns preclude its development in humans. First, in vivo nef repair and evolution occurs in SIV-infected macaques (Whatmore et al. 1995), and pathogenicity is at least partially retained both in macaques infected with SIVΔnef (Baba et al. 1995; Cohen 1997) and in humans infected with nef-deleted HIV-1 (Mariani et al. 1996).

These considerations have directed most vaccine efforts toward newer strategies that employ synthetic envelope protein subunits or HIV-1 protein expression via recombinant viral vectors with HIV-specific inserts, or naked DNA. Heterologous prime-boost approaches are frequently used because of the early observation that such regimens often strengthen and broaden HIV-specific immune responses (Cooney et al. 1993; Excler and Plotkin 1997; Ranasinghe and Ramshaw 2009). Prime-boost strategies are not new to medical science: Knowledge that naturally occurring immune responses may be boosted has existed since Robert Koch showed that microbe-derived antigen provoked an immune response at injection sites in tuberculosis patients (Burke 1993). More than 100 NHP and human clinical trials have evaluated prime-boost HIV-1 vaccine strategies (Paris et al. 2010). In this article, we focus on HIV preventive vaccine strategies that have progressed to at least phase II human testing (Table 1).

MODELING HIV VACCINE DEVELOPMENT

Studies evaluating chronically HIV-1-infected individuals have led to many important insights that inform vaccine development. For a complete discussion of HIV-1 pathogenesis, please refer to Lackner et al. (2011).
### Table 1. Completed phase II and III human HIV-1 vaccine trials

<table>
<thead>
<tr>
<th>Category</th>
<th>Study protocol</th>
<th>Candidate vaccine</th>
<th>Phase</th>
<th>Volunteers</th>
<th>Location</th>
<th>Year published</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pox-protein</td>
<td>RV144</td>
<td>AIVAC-HIV vCP1521/AIDSVAX MN-CM244</td>
<td>III</td>
<td>16,403</td>
<td>Thailand</td>
<td>2009</td>
<td>31% efficacy</td>
</tr>
<tr>
<td>Pox-protein</td>
<td>HVTN203</td>
<td>AIVAC vCP1452/MN-GNE8 rgp120 (B)</td>
<td>II</td>
<td>330</td>
<td>US</td>
<td>2007</td>
<td>Interferon-γ ELISpot in 16% of volunteers</td>
</tr>
<tr>
<td>Pox-protein</td>
<td>HIVNET 026</td>
<td>AIVAC vCP1452/MN rgp120 (B)</td>
<td>II</td>
<td>200</td>
<td>Multinational</td>
<td>2007</td>
<td>Not immunogenic</td>
</tr>
<tr>
<td>Pox-protein</td>
<td>A/EG 202/</td>
<td>AIVAC-HIV vCP205/SF2 rgp120 (B)</td>
<td>II</td>
<td>420</td>
<td>US</td>
<td>2001</td>
<td>CD8⁺ T cells in 33% of volunteers</td>
</tr>
<tr>
<td>Pox-protein</td>
<td>HIVNET 014</td>
<td>DNA-HIVA/AIDSVAX (A)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA-pox</td>
<td>IAV1 010</td>
<td>DNA-HIVA/MVA-HIVA (A)</td>
<td>Ia</td>
<td>115</td>
<td>East Africa</td>
<td>2007</td>
<td>Rare interferon-γ ELISpot responses</td>
</tr>
<tr>
<td>DNA-pox</td>
<td>HVTN 205</td>
<td>GeoVax JS7 DNA/MVA HIV62 (B)</td>
<td>II</td>
<td>225</td>
<td>US, Peru, RSA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA-Ad5</td>
<td>RV 172</td>
<td>DNA (VRC-HIVDNA016-00-VP)/rAd5(VRC-HIVADV014-00-VP (A, B, and C)</td>
<td>1/IIa</td>
<td>324</td>
<td>East Africa</td>
<td>2010</td>
<td>Interferon-γ ELISpot in 63% of volunteers</td>
</tr>
<tr>
<td>DNA-Ad5</td>
<td>HVTN 204</td>
<td>DNA (VRC-HIVDNA016-00-VP)/rAd5(VRC-HIVADV014-00-VP (A, B, and C)</td>
<td>Ia</td>
<td>480</td>
<td>Americas, RSA</td>
<td></td>
<td>Interferon-γ ELISpot in &gt;60% of volunteers</td>
</tr>
<tr>
<td>DNA-Ad5</td>
<td>HVTN 505</td>
<td>DNA (VRC-HIVDNA016-00-VP)/rAd5(VRC-HIVADV014-00-VP (A, B, and C)</td>
<td>Iib</td>
<td>1350</td>
<td>US</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>DNA-Ad5</td>
<td>HVTN 502/Merck 203</td>
<td>MRKA5 HIV-1 gag/pol/nef</td>
<td>Iib</td>
<td>3000</td>
<td>US</td>
<td>2008</td>
<td>No efficacy; transient infection risk</td>
</tr>
<tr>
<td>DNA-Ad5</td>
<td>HVTN 503</td>
<td>MRKA5 HIV-1 gag/pol/nef</td>
<td>I/IIa</td>
<td>3000</td>
<td>RSA</td>
<td></td>
<td>No efficacy</td>
</tr>
<tr>
<td>Pox-protein</td>
<td>ACTG 326/PACTG 326</td>
<td>AIVAC-HIV vCP1452/AIDSVAX B/B</td>
<td>I</td>
<td>48</td>
<td>US</td>
<td>2005</td>
<td>Safe, poorly immunogenic</td>
</tr>
<tr>
<td>Peptide</td>
<td>ANRS VAC 18</td>
<td>LIPO-5</td>
<td>II</td>
<td>156</td>
<td>France</td>
<td>2010</td>
<td>CD8⁺ responses in &gt;60%</td>
</tr>
<tr>
<td>Protein-protein</td>
<td>A/EG 201</td>
<td>rgp120/HIV-1 SF-2/MN rgp120</td>
<td>II</td>
<td>296</td>
<td>US</td>
<td>2000</td>
<td>NAb in 87%, DTH to gp120 in 59% of volunteers</td>
</tr>
<tr>
<td>AAV</td>
<td>IAV1 A002</td>
<td>tgAA1C09</td>
<td>II</td>
<td>84</td>
<td>RSA, Uganda, Zambia</td>
<td>2010</td>
<td>Interferon-γ ELISpot in 25% of volunteers</td>
</tr>
<tr>
<td>Protein</td>
<td>VAX 003</td>
<td>AIDSVAX B/E</td>
<td>III</td>
<td>2500</td>
<td>Thailand</td>
<td>2006</td>
<td>No efficacy</td>
</tr>
<tr>
<td>Protein</td>
<td>VAX 004</td>
<td>AIDSVAX B/B</td>
<td>III</td>
<td>5400</td>
<td>US</td>
<td>2005</td>
<td>No efficacy</td>
</tr>
</tbody>
</table>

Shown are completed clinical HIV vaccine trials grouped by vaccine types (Category). Pox, recombinant poxvirus-vectorized vaccine; DNA, deoxyribonucleic acid; Ad5, recombinant adenovirus 5-vectorized vaccine; US, United States; RSA, Republic of South Africa; Nab, neutralizing antibodies; DTH, delayed type hypersensitivity.
Acute Infection

HIV infection acquired sexually begins in CD4\(^+\) T cells or macrophages in vaginal or rectal mucosa and remains confined to mucosa or regional lymphoid tissue for a few days during the “eclipse phase” before exponential replication of virus in plasma and establishment of the reservoir (McMichael et al. 2010). Unfortunately, immune responses elicited by HIV-1 infection fail to prevent infection. However, many insights from these well-characterized adaptive and innate responses offer hope that optimized vaccine-induced responses may be protective. Studies of acutely HIV-1 infected humans have shown that the majority of sexually acquired infections are caused by a single transmitted-founder (T/F) virus (Keele et al. 2008; Abrahams et al. 2009; Salazar-Gonzalez et al. 2009). Unlike viruses circulating in chronically infected humans, T/F viruses are more likely to be CCR5-tropic and are less macrophage-tropic (Salazar-Gonzalez et al. 2009). Initial viral uniformity could make the virus more easily neutralized if an effective immune response were present at the time of exposure. Adaptive cellular (CD8\(^+\)) immune responses drive both viral suppression and diversity through escape mutants (Goonetilleke et al. 2009; Treurnicht et al. 2010). Similarly, HIV-specific antibody responses, which typically mature over time, significantly shape the generation of neutralization escape mutants but fail to neutralize contemporaneous strains (Richman et al. 2003; Wei et al. 2003; Moore et al. 2009).

Nonhuman Primate Models

Nonhuman primate (NHP) models have provided important insights into HIV-1 vaccine development. Four models utilizing different viruses or host species have been used: HIV-1/chimpanzee, HIV-2/macaque, SIV/macaque, and SHIV/macaque. The SIV/macaque and SHIV/macaque models are currently most commonly used because of low levels of HIV replication, prolonged time to progression, and high cost of HIV-2 and chimpanzee models (Franchini et al. 2004). NHP experiments inform vaccine development through elegant experiments aimed at elucidation of SIV or SHIV pathogenesis or vaccine performance. An SIV-macaque study showed increased survival, reduction in viremia, and preservation of central memory CD4\(^+\) T lymphocytes following delivery of a plasmid DNA prime followed by type 5 Adenovirus vector boost vaccine (Letvin et al. 2006). This study, along with human immunogenicity data from phase I studies, raised enthusiasm for an ongoing phase IIB efficacy study of these vaccines (ClinicalTrials.gov, NCT00865566), in the HIV Vaccine Trial Network (HVTN) 505 protocol. A similar approach using a SHIV/macaque model (Shiver et al. 2002) failed to predict the lack of efficacy in a phase IIB evaluation of the Merck Ad5 gag/pol/nef vaccine (Buchbinder et al. 2008). This vaccine failed to show postinfection viremic control in a SIV challenge model (Casimiro et al. 2005). Unfortunately, there are no animal models that accurately predict efficacy in humans. High-dose challenge NHP models are potentially confounded by high SIV challenge doses used to achieve 100% infection rates after a single exposure in placebo animals (McDermott et al. 2004). Repeated mucosal challenges with a lower dose of virus (10–50 TCID\(_{50}\)) may more accurately approach human exposure conditions, but such studies remain to be correlated with human clinical trial outcomes.

DNA AND PROTEIN SUBUNIT VACCINE TRIALS

Protein Subunit Alone

Initial clinical trials of candidate HIV vaccines in the late 1980s and early 1990s attempted to follow the template for hepatitis B vaccine: Use recombinant subunits or synthetic peptide fragments to elicit neutralizing antibodies against viral antigens expressed on the virion surface. For HIV-1, these are the Env proteins gp120 and gp41. These antigens typically elicit strong binding antibody, limited neutralizing antibody (Nab) and CD4\(^+\), T-cell responses (Pantophlet and Burton 2006).
Following a phase I/II trial that showed safety and immunogenicity (Belshe et al. 1994), the first phase III efficacy trial of a prophylactic HIV-1 vaccine (VAX 004) investigated a recombinant HIV-1 envelope glycoprotein subunit (rgp120) derived from MN, a laboratory-grown strain, and a second envelope derived from a clade B primary isolate (GNE8) (AIDSVAX B/B’) in alum adjuvant. Study participants were men who have sex with men and women at high risk for heterosexual transmission of HIV-1 from 61 sites in the United States, Puerto Rico, Canada, or the Netherlands (Harro et al. 2004; Flynn et al. 2005). Participants received vaccine or placebo at months 0, 1, 6, 12, 18, 24, and 30. Infection rates among the 3598 vaccinees and 1805 placebo recipients were similar at 6.7% and 7.0%, respectively. There were no differences in postinfection secondary end points including viral load, CD4\(^+\) T-cell count, time interval to initiation of antiretroviral therapy, or genetic characteristics of the infecting virus. Vaccine induced binding antibody responses were inversely correlated with risk of infection. For all eight antibody variables, the mean responses tended to be slightly higher in uninfected vaccinees than in infected vaccinees, suggesting that such antibody responses either (1) caused both increased (low responders) and decreased (high responders) risk of HIV acquisition or (2) represented a correlate as opposed to causative mechanism for enhanced HIV-1 acquisition. There was some suggestion that there were both higher antibody titers and protection in African-American subjects, but incorporation of a correction for multiple sampling diminished this finding. Neutralizing antibodies did not correlate with infection incidence (Gilbert et al. 2005).

Following the demonstration of safety and immunogenicity in a phase I/II trial in Bangkok, Thailand (Pitisuttithum et al. 2004), a second phase III efficacy trial of a vaccine candidate was undertaken (VAX003). This study represented the first efficacy trial conducted in a developing country, and it was the first to exclusively study an intravenous drug user (IDU) population. The vaccine contained two different rgp120 antigens, one from subtype B MN, and the other from a primary isolate CRF_AE (A244) produced in Chinese hamster ovary (CHO) cells in alum adjuvant. A total of 2546 IDUs were enrolled between March 1999 and August 2000 and received vaccine or placebo at months 0, 1, 6, 12, 18, 24, and 36. Adverse events were rare and occurred with equal frequency among vaccine and placebo recipients. Vaccine efficacy was estimated at 0.1% (95% CI, −30.8% to 23.8%), and no effect was observed on secondary end points (Pitisuttithum et al. 2006; Pitisuttithum 2008).

Among 2099 uninfected subjects in phase I and II trials of Env-based subunit AIDS vaccines, 23 were diagnosed with intercurrent HIV-1 infection. There were no significant differences in secondary end points, including virus load, CD4 lymphocyte count, or V3 loop amino acid sequence (Graham et al. 1998).

Further nonprespecified analyses of Vax 004 antibody-directed cell-mediated viral inhibition (ADCVI) showed an inverse correlation between ADCVI levels and HIV acquisition. This effect was influenced by Fc-\(\gamma\) IIa and IIIa polymorphisms (Forthal et al. 2007). More recently, Gilbert et al. reported low levels of neutralizing antibody against Tier 2 isolates in Vax 004 (Gilbert et al. 2010); however, when the same data are analyzed using two different assays (Monogram and TZM-bl), there appeared to be an inverse correlation between breadth of (low-level) Tier 2 neutralization and infection (B Korber, unpubl.).

**DNA Prime Protein Subunit Boost**

Strategies employing DNA prime followed by protein boost have only been studied in a single published phase I human trial. A polyvalent DNA prime vaccine containing five plasmids each encoding a codon-optimized protein including gp120 sequences from subtypes A, B, C, and E, as well as a sixth plasmid encoding a subtype C gag gene was performed. Protein boost components included equal parts of five gp120 proteins matching those used in DNA prime components formulated with QS-21 adjuvant and excipient cyclodextrin (Wang...
et al. 2008). DNA vaccination was administered in two different doses intramuscularly (IM), as well as in one dose intradermally (ID). The vaccine strategy elicited cross-subtype HIV-specific T cell responses as well as high titer serum antibody responses against HIV-1 viruses with diverse genetic backgrounds. These results were tempered by observations of delayed type hypersensitivity in 43% of subjects following protein vaccination, and two cases of vasculitis temporally related to inoculation with recombinant Env protein + QS21 adjuvant (Kennedy et al. 2008).

Early naked DNA plasmid vaccines given alone were poorly immunogenic and responses lacked durability (MacGregor et al. 1998, 2000, 2002; Wang et al. 1998; Roy et al. 2000). Such observations have led to pursuit of alternative strategies to enhance immune responses (Abdulhaqq and Weiner 2008), and contemporary strategies typically use DNA vaccines as a “prime” with a heterologous boost. Electroporation is a promising approach that has been used to enhance in vivo transfection rates in nonhuman primates (Rosati et al. 2008; Patel et al. 2010) and more recently in several phase I HIV-1 preventive DNA vaccine human trials (Vasan et al. 2009; clinicaltrials.gov NCT00991354 and NCT01260727).

**PEPTIDE VACCINE TRIALS**

Several synthetic peptide constructs have been investigated as potential preventive HIV-1 vaccines. Sequences from the envelope V3 loop induce Nab in some laboratory animals but were tolerogenic in macaques and chimpanzees. An octameric V3 multiple antigen peptide formulated in alum was found to be safe but generated neither consistent nor robust lymphoproliferative responses in human volunteers (Kelleher et al. 1997). Peptides do not usually induce a class I-restricted CD8+ response in vivo, but some lipopeptides elicit such a response (Deres et al. 1989; Deprez et al. 1996). Building on this concept, a phase II human trial evaluated HIV-LIPO-5 vaccine (five long peptides, Gag17–35, 253–284, Pol325–355, Nef66–97, and 116–145, containing multiple CD8+ and CD4+ epitopes, coupled to a palmitoyl tail) in 132 volunteers. Vaccination, which was given IM at one of three doses at weeks 0, 4, 12, and 24, elicited CD8+ responses as measured by IFN-γ ELISpot in two-thirds of vaccine recipients regardless of dose, and CD4+ responses as measured by PBMC lymphoproliferation in approximately half of vaccine recipients regardless of dose (Salmon-Cérón et al. 2010). Future studies will likely incorporate lipopeptides in prime-boost regimens.

**ADENOVIRAL VECTOR VACCINE TRIALS**

DNA and adenovirus constructs have been some of the most extensively tested in the NHP model. Enthusiasm for Merck DNA–Ad5 was generated by the comparative study by Shiver et al. in which macaques that received either DNA–Ad5 or Ad5 alone, and were challenged with a homologous SIV with an HIV-derived envelope (SHIV)89.6P virus, controlled viral replication better than monkeys that received rMV A (Shiver et al. 2002). A postinfection viral load reduction was not seen when SIV-mac239 was the challenge virus (Casimiro et al. 2005). The results of the Merck Step trial (discussed in the following paragraphs) have led to a reevaluation of the NHP challenge model, in particular, questions about dose (low vs. high dose), route (intravenous vs. mucosal), SHIV versus SIV challenge, virus challenge stock (single clone vs. “swarm,” heterologous vs. homologous), as well as end points (Fauci et al. 2008; Watkins et al. 2008). Recently, statistically significant differences in control of viral replication after challenge have been observed in the macaque model using a heterologous challenge with SIVsmE660 after vaccination with DNA–Ad5 that expresses all HIV proteins except Env from SIVmac239 (Wilson et al. 2009). DNA-Ad5 SIV-based vaccines protected against an SIVsmE660 acquisition after low-dose intrarectal challenge (Letvin et al. 2011). Adenovirus serotypes that are less commonly associated with human disease have also recently been developed to overcome problems with preexisting immunity, and Ad26 and 35 vaccines are now in a Phase I clinical trial.
(Baden et al. 2009). Results from NHP challenge studies are encouraging—particularly the strategy of priming with Ad5 and boosting with Ad26, which was associated with a 2.4 log reduction in set-point viral load and improved survival compared with control animals (Liu et al. 2009).

The most extensively tested of the adenoviral vector vaccine candidates in human trials is Merck’s replication-defective Ad5, containing clade B gag, pol, and nef gene inserts. This candidate was advanced to a Phase Ib efficacy evaluation that was stopped at a scheduled interim analysis when it was apparent that there was no effect on postinfection viral RNA level (Buchbinder et al. 2008), despite demonstration of apparent immunogenicity in Phase I clinical trials and evidence of viral load control in the SHIV/NHP model (Shiver et al. 2002; Casimiro et al. 2003; Wilson et al. 2006; Priddy et al. 2008; Harro et al. 2009; Asmuth et al. 2010). Although mechanisms underlying failure of this vaccine remain elusive, one explanation is that this homologous vector vaccine, which elicits frequent IFN-γ ELISpot responses (77% of vaccinees overall) when given in three doses, generates a limited breadth of antigen-specific responses (McElrath et al. 2008). Likewise, the absolute level of IFN-γ ELISpot may have been too low, or given the inferior IFN-γ ELISpot generation by the ALVAC + AIDSVAX B/ E combination, the ELISpot assay may not measure relevant responses. Intense study evaluated initial vaccine-related enhancement of infection among a subgroup of anti-Ad5 positive uncircumcised men who have sex with men (MSM) (Buchbinder and Duerr 2009; D’Souza and Frahm 2010). Extended follow-up analyses (Benlahrech et al. 2009; Masek-Hammerman et al. 2010) have indicated that increased risk of acquisition decreased over time. The significance and potential mechanism of vaccination-enhanced acquisition among uncircumcised men is unclear, therefore a cautious approach has been taken with Ad5-vectored gag/pol/nef vaccines, especially in uncircumcised MSM (Duerr et al. 2010).

The NIH/NIAID Vaccine Research Center has also developed a DNA–rAd5 prime-boost regimen, which has been extensively tested for safety and immunogenicity, and a Phase Ib efficacy, test-of-concept trial is ongoing in the United States (HVTN 505) among circumcised men who have sex with men and lack preexisting antivector-NAbs. The first DNA–rAd5 combination consisted of four separate DNA plasmids (VRC-HIVDNA009–00-VP): One plasmid with gene inserts for gag (clade B strain HXB2), pol (clade B NL4–3), and nef (clade B, PV22) with mutations in gag and pol to prevent enzymatic activity, creating a fusion protein product that does not produce pseudovirions. Env genes from clades A (92RW020), B (HXB2), and C (97ZA012) were truncated immediately downstream from the transmembrane domain of gp41, along with other deletions, to create three gp145-expressing plasmids. For the rAd5 boost (VRC-HIVADV014–00-VP), four separate vectors were produced with the same inserts (clade/strain matched) expressing a Gag/Pol polyprotein along with gp140 versions of Env. Nef was not included in Ad5 as the vectors were not stable. Separate Phase I dose-ranging trials of each of these products showed that the plasmid DNA was similarly immunogenic at the 4 (n = 20) or 8 mg (n = 15) doses with 100% and 93% with CD4⁺ responses by ICS, respectively, and 35% and 33% with CD8⁺ responses, respectively, with both T-cell subsets exhibiting more Env-specific responses. The rAd5-vectored HIV-immunogens generated ELISpot responses in 22 out of 30 patients (73%), with 28 out of 30 patients having a detectable CD4⁺ response and 18 out of 30 patients a CD8⁺ response by ICS at week 4 (peak immunogenicity) after a single IM dose, and mostly Env-specific. Although no Nab were detected in either the DNA or rAd5 trials, Env-specific binding antibody responses measured using ELISA were detected in 50% and 71% of rAd5 and DNA recipients, respectively (Catanzaro et al. 2006, 2007; Graham et al. 2006).

These constructs were subsequently tested in three Phase IIa trials, IAVI V001, HVTN 204, and RV172 (Kibuuka et al. 2010). In the RV172 study, the VRC DNA (VRC-HIVDNA-016–00-VP) tested was a six-plasmid mixture.
encoding HIV env from subtypes A, B, and C, and subtype B gag, pol, and nef, and VRC-HIVADV014–00-VP. Volunteers were randomized to receive either $10^{10}$ ($n = 24$) or $10^{11}$ ($n = 24$) particle units (PUs) of rAd5 on day 0 only; 4 mg of DNA at 0, 1, and 2 months, followed by rAd5 at either $10^{10}$ ($n = 114$) or $10^{11}$ PUs ($n = 24$) boosting at 6 months. HIV-specific T-cell responses were detected in 63% of vaccinees. ELISpot responses for DNA prime with low-dose (63%) or high-dose (60%) rAd5 were similar—positive responses were predominantly to Env peptides, followed by Pol or Gag, regardless of the immunization regimen. The high-dose rAd5 boost had the highest frequency of responders to all three antigens tested (Env, Gag, or Pol), whereas responses were approximately equal for the other immunization groups for two antigens (20%–26%). Preexisting Ad5-NAbs did not appear to affect the frequency or magnitude of T-cell responses in the prime-boost vaccinees. Response rates in participants that received rAd5 alone were lower, but not statistically significant.

**Rare Serotype Ad Vectors**

Antivector immunity against adenovirus vectors varies by population and serotype. Ad5 and Ad35 seropositivity was detected in 60% and 7%, respectively, in individuals at risk for AIDS, respectively, living in the Netherlands, and 90% vs. 20% among those living in sub-Saharan Africa (Kostense et al. 2004). Vector neutralization threatens to attenuate immunogenicity, prompting construction of vectors using Ad serotypes that have lower frequencies of natural infection in humans, such as Ad36 and Ad26 (Barouch 2010).

**POXVIRUS AND PROTEIN SUBUNIT PRIME-BOOST VACCINE TRIALS**

Poxviruses have properties that make them excellent expression systems. Characteristics such as large capacity for integration of foreign DNA (more than 25,000 base pairs for vaccinia virus [VV]) and cytoplasmic gene expression are possessed by members of the poxviridae family. Successful recombinant gene expression using poxvirus was first shown in 1982 and has been used for such diverse activities as analysis of protein structure/function relationships, protein processing and intracellular trafficking, antigen presentation, and the determinants of cellular and humoral immunity, and live recombinant vaccines. Meaningful differences among poxviridae include host specificity and susceptibility to antivector host immunity (Paoletti 1996; Carroll and Moss 1997).

**Vaccinia Vectors**

Modified Vaccinia Ankara (MVA) was initially developed near the end of the smallpox eradication program by the technique of passaging virus about 500 times on primary chicken embryo fibroblasts (Franchini et al. 2004). Multiple resultant genetic deletions have rendered MVA unable to replicate in most mammalian cells, which is a likely explanation for its excellent safety record: It was assessed as a smallpox vaccine in over 120,000 recipients in Germany without significant adverse reactions. Its large genome renders it amenable to genetic manipulation, making it an ideal candidate vector for vaccine development (Moss 1991; Moss et al. 1996; Blanchard et al. 1998; Sutter and Staib 2003).

Macaque-SIV studies of DNA followed by MVA-vectored boost vaccination showed induction of CTL responses, primarily to a single SIV gag epitope (Hanke et al. 1999; Allen et al. 2000). Given alone IM, MVA-based vaccines have been shown to be safe and immunogenic in human clinical trials (Cebere et al. 2006; Dorrell et al. 2007; Peters et al. 2007; Jaoko et al. 2008). Antivector immunity is an important consideration: Many older adults as well as most members of the U.S. military have been inoculated with vaccinia and thus have at least some degree of antivaccinia immunity.

The first report of immunogenicity data for using prime-boost DNA/MVA vaccine approach evaluated pTHr–HIVA plasmid DNA and MVA–HIVA prime-boost combination, after initial Phase I safety testing (Mwau et al. 2004; Cebere et al. 2006). The HIVA immunogen contained consensus clade A Gag p24/p17
sequences and a string of CTL epitopes inserted into plasmid DNA, and the same immunogens as a transgene insert in recombinant MVA (rMVA). Safety was first shown in several small trials (IAVI 001, IAVI 003 and IAVI 005), followed by Phase I/II studies. Only one antibody response to p24/p17 was detected in any of the participants in these studies (Mwau et al. 2004; Cebere et al. 2006; Jaoko et al. 2008). In the IAVI 006 study, 119 volunteers were randomized into several arms and received pTHr–HIV A DNA in a dose of 0, 0.5, or 2.0 mg in two doses IM, followed by two doses of $5 \times 10^7$ rMVA after 4 or 16 weeks. Using a fresh peripheral blood mononuclear cell (PBMC) IFN-γ ELISpot assay, less than 15% of vaccine recipients had transient HIV-specific Gag responses, with no significant effect of DNA priming observed (Hanke et al. 2007; Guimaraes-Walker et al. 2008). In IAVI 016, 24 volunteers received either two doses of rMVA alone at the higher dose of $2.5 \times 10^8$ plaque-forming units (pfu) or two doses of pTHr–HIVA DNA at a higher dose of 4 mg (Casimiro et al. 2003; Goonetilleke et al. 2006; Peters et al. 2007; Baden et al. 2009). In this study, immunomonitoring was conducted by ex vivo ELISpot, a “cultured” ELISpot using a 10-d, peptide-stimulated PBMC expansion step, and polyclonal or multicolor flow cytometry. No antigen-specific responses were detected by the validated ex vivo ELISpot in the rMVA-only group, while four of eight in the DNA–rMVA group had responses. In the “cultured” ELISpot assay, five of eight in the rMVA-only group had responses, while all of those who received DNA–rMVA had Gag-specific responses. This modified ELISpot format detected predominantly CD4+ T-cell responses, with two vaccinees having CD8+ responses, which were of greater magnitude and breadth in those who received the DNA–rMVA combination compared with the two doses of rMVA. Larger trials at these higher doses are ongoing (IAVI 2010).

Another DNA–MVA prime-boost Phase I study, HIVIS 02, has been conducted. This study utilized plasmid DNA constructs developed at the Karolinska Institute, and the Walter Reed Army Institute of Research/ National Institutes of Health (WRAIR/NIH)-produced recombinant MVA-CMDR (Chiang Mai Double Recombinant), which has inserts based on CRF01_AE isolates from Thailand that express gp150 (CM235), gag and pol, with a deleted integrase and nonfunctional reverse transcriptase (CM240). MVA-CMDR was shown to be safe and immunogenic in a separate Phase I trial (Currier and de Souza 2009). A total of 40 healthy HIV-negative participants were randomized into four groups ($n = 10$ per group) and injected with seven DNA plasmids expressing subtypes A, B, and C gp160 env; B rev; subtype A and B p17/p24 gag, and clade B rt-mut. The DNA priming dose was administered ID or IM with or without recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) using the Biojector 2000. A single boost of MVA-CMDR was given 6 months after the last DNA injection at either $10^7$ pfu ID or $10^8$ pfu IM. Eleven of 37 (30%) had positive ELISpot after DNA alone, whereas significant boosting was observed after MVA-CMDR with 34 of 37 (92%) vaccinees responding (32 to Gag and 24 to Env). One mg of DNA administered ID was as effective as 4 mg of DNA IM as a prime for the MVA-CMDR boost. In addition, 68% had an IL-2 ELISpot response and 92% a HIV-1-specific lymphocyte proliferation assay (LPA) response. These results were confirmed in a second study conducted in Tanzania (Aboud et al. 2010). A comparison of these DNA vectors delivered by Biojector and electroporation with subsequent rMVA boosting will evaluate the role of DNA delivery route (clinicaltrials.gov NCT01260727).

The GeoVax clade B DNA–MVA was tested in HVTN 065. Volunteers received IM DNA and MVA that expressed clade B Gag, Pol, and Env, with DNA given at 0 and 2 months and boosted at months 4 and 6 with MVA. Both low- (0.3 mg of DNA and 107 of the 50% tissue culture infective dose [TCID50] of MVA) and high-dose (3 mg of DNA and 108 TCID50 of MVA) formulations were tested. Preliminary results showed similar T-cell responses in low- and high-dose groups. In the high-dose group, 75% of volunteers had CD4 and 37% had...
CD8 T-cell responses. Cosecretion of IL-2 and IFN-γ was observed in 82% of CD4 and 67% of CD8 responses at the peak immunogenicity time point (Robinson et al. 2008). Additional DNA/MVA candidates based on subtype C (TBC-M4 MVA) and recombinant B/C antigens (ADVAX DNA and ADMVA) have completed Phase I testing, but none in combination. ADVAX DNA given alone at 0, 1, and 3 months showed ELISpot responses in four of 12 high-dose recipients, whereas the MVA constructs (given IM at 0, 1, and 6 months) were more immunogenic, with ELISpot positivity in 60%–100% of vaccine recipients at the highest dose given (Ramanathan et al. 2009; Vasan et al. 2010a,b).

Despite initially disappointing results with the DNA–MVA prime-boost approach (Guimaraes-Walke et al. 2008), more recent studies are promising. Effects of MVA boost appear consistent with differences in immunogenicity probably because of DNA priming and dose (Hanke et al. 2007). One concern with using MVA as a vector is the presence of preexisting immunity to vaccinia, which may affect the magnitude and quality of immune responses, as shown with recombinant Ad5 vaccine vector (Priddy et al. 2008; Harro et al. 2009). However, data from the HIVIS-02 study indicate that only the magnitude of the response was attenuated, whereas the frequency of responders was maintained in those with preexisting vaccinia immunity (Gudmundsdotter et al. 2009; Barouch 2010).

NYVAC was derived from VC-2, a plaque-cloned isolate of the COPENHAGEN vaccinia strain. NYVAC construction entailed deletion of 18 open reading frames encoding for replication competency in mammalian cells and virulence factors (Tartaglia et al. 1992).

The EuroVacc 02 Phase I trial evaluated recombinant DNA and NYVAC, which express matched immunogens containing gag, pol, env, and nef sequences from a Chinese clade B and C recombinant virus isolate, 97CN54 (CRF70_B/C'). Forty volunteers received DNA C or placebo on day 0 and at week 4, followed by NYVAC C boosting (20 received DNA/ NYVAC) at weeks 20 and 24. A total of 90% showed IFN-γ ELISpot responses compared with 33% who received NYVAC alone. T-cell responses were of relatively high magnitude, with CD4+ (16 of 18 assessed) more frequent than CD8+ responses (eight of 16). Responses were skewed toward Env (91% of vaccinees), with 48% responding to Gag, Pol, or Nef. Responses after NYVAC boost compared with NYVAC alone suggest that DNA priming was occurring, even when no immune response was detected after the second dose of DNA (Harari et al. 2008). Induced T cells were typically polyfunctional, with 60% exhibiting two to three functions, and both CD4+ and CD8+ T cells typically expressing IFN-γ, IL-2, and TNF-γ. Prime-boost regimens with DNA and poxvirus vectors appear to induce polyfunctional T-cell responses that are biased toward Env-specific T-cell responses, with a predominance of CD4+ over CD8+ T-cell responses.

Canarypox Vectors

ALVAC is a recombinant canarypox virus (CPV)-based vector that functions as an immunization vehicle by expressing gene products in the absence of productive viral replication (Tartaglia et al. 1992). Although there are no licensed ALVAC-based human vaccines, commercial production feasibility is clearly shown by current marketing of five licensed veterinary canarypox-based vaccines: Recombitek (Canine distemper), Purevax (rabies[cats]), Recombitek WNV (West Nile [equine]), Eurifel (feline leukemia), and Proteqflu (influenza[horses]) (Merial 2010). Because CPV is a bird pathogen, canarypox recombinant vectors infect but are unable to replicate in humans, predicting that they will not disseminate in vaccine recipients nor be transmitted to unvaccinated contacts (Taylor et al. 1988; Baxby and Paoletti 1992).

In both guinea pig and macaque models, gp160 MN/LAI-2 significantly boosted antibody responses primed with ALVAC-HIV (Excler and Plotkin 1997; Jaoko et al. 2008). ALVAC-HIV-1 expressing homologous vaccine native Env proteins protected macaques from high-dose mucosal challenge, and this protection was better when gp120 antigen was
included in the vaccine (Pialoux et al. 1995; Excler and Plotkin 1997). ALVAC-SIV given to neonatal macaques protected against low dose SIV challenge in milk; interestingly, an MVA-SIV vaccine developed better ELISpot responses but did not protect (Van Rompay et al. 2005).

Multiple HIV-1 inserts have been inserted into ALVAC vectors, yielding extensive safety and immunogenicity data in humans (Gilbert et al. 2003; de Bruyn et al. 2004). Phase I human trials with recombinant canarypox vectors have shown induction of CD8<sup>+</sup> CTL (notably these are after in vitro stimulation; when direct ex vivo IFN-g or CD107 expression is measured, CD8<sup>+</sup> CTL are not identified). However, only 15%–30% of subjects have such responses at any given time postvaccination (Belshe et al. 1998, 2001; Clements-Mann et al. 1998; Evans et al. 1999; Salmon-Céron et al. 1999). Three recombinant ALVAC HIV-1 vaccines have advanced to Phase II studies.

ALVAC-HIV vCP205 expresses four gene products: Gag p55 protein from the HIV-1 LAI strain, p15 protein, a portion of the protease gene from the HIV-1 MN strain, and the anchoring transmembrane region of gp41 from the HIV-1 LAI strain (Paris et al. 2010). This recombinant vector was studied in a phase II trial conducted in the US among 60 study participants at lower risk for HIV-1 infection and 375 individuals at higher risk for HIV-1 infection. ALVAC-HIV vCP205 was given with or without an SF-2 rgp120 boost at 0, 1, 3, and 6 months (Belshe et al. 2001). More than 90% of combination regimen recipients developed Nab responses against homologous TCLA virus, and approximately one-third of those who received vCP205-containing regimens developed anti-HIV CTL responses, without differences in immune responses among the higher and lower risk groups.

More complex ALVAC vectors, vCP1433 and vCP1452, were designed to provide better gene expression and more durable CD8<sup>+</sup> CTL responses. Both express gag, protease, nef, and pol genes, and a part of the env gene expressing the gp120 and anchoring region of gp41. The ALVAC vCP1452 vector was modified by insertion of two vaccinia virus-coding sequences (E3L and K3L) to enhance expression efficiency in ALVAC-infected human cells. In large, phase II studies, HVTN 203 and HIVNET 026, vCP1452 was boosted with the bivalent rgp120-containing sequence from the clade B primary isolate GNE8 as well as MN. Cellular immunogenicity in this study was not deemed sufficient to proceed with a planned Phase III immune correlates trial (Russell et al. 2007).

Two Phase I/II trials of vCP1521, which is similar to vCP205 except for a different env, 92Th023 gp120 (CRF01_AE), substituted for MN, in combination with three different subunit boosts have been conducted in Thailand. In RV132 (vCP1521 + oligomeric rgp160 92TH023/polyporphosazene or rgp120 CM235/SF2/MF59), the majority of recipients (68%–93%) developed either SF2, TH023 or CM235 lymphoproliferative responses to gp120 antigens. In RV132, Nab to the TCLA subtype E strain NPO3 was found in 84% and 89% of recipients of vCP1521 + gp160 TH023 or gp120 CM235/SF2, respectively. In total, 96% and 100% of vCP1521 + gp160 TH023 and vCP1521 + gp120 CM235/SF2 prime-boost recipients had Nab against any subtype E-adapted HIV-1, respectively. Neutralization of homologous and heterologous laboratory-adapted strains of HIV-1 was observed for the majority of vaccine recipients in both prime-boost arms. Cross-neutralization of SF2 by recipients of oligomeric gp160 (27%) was also observed. The Nab response observed for subjects boosted with bivalent gp120 B/CRF01_AE was similar to a previous clinical trial of these antigens among Thai volunteers (Pitisuttithum et al. 2003). In that study, 84% and 96% of volunteers who received both vaccine antigens had Nab to NPO3 and SF2, respectively. Some data suggest that oligomeric antigens may be more likely to induce relevant Nab, although this was not seen in relation to the heterologous CM244 strain in a PBMC-based neutralization assay (Fouts et al. 1997; VanCott et al. 1997). HIV-specific CD8<sup>+</sup> CTLs were detected in 11% and 25% of prime-boost recipients in the gp160 TH023 + gp120
CM235/SF2 arms of RV132, respectively (Thongcharoen et al. 2007).
In RV135, 58% and 67% of persons receiving vCP1521 plus high- or low-dose rgp120 (MN/A244) in alum developed A244-specific proliferative responses, whereas 71% had a Nab response against subtype E-adapted HIV-1. HIV-specific CD$^+$ CTLs were identified in 23% of vaccinees receiving either boost (Nitayaphan et al. 2004). Significant ADCC activity was also observed in over 85% of vaccine recipients to either clade B or CRF01_AE gp120 (Karnasuta et al. 2005). The VCP1521 prime and high-dose 300 $\mu$g of MN and 300 $\mu$g of A244 boost was chosen for use in a Phase IIb efficacy trial, RV144.

**RV144—Proof of Concept for Protective Efficacy**
As neither the oligomeric gp160 92TH023 or the bivalent gp120 B/E vaccine were available for further testing, the vaccine combination in RV135, which had passed the predetermined immunogenicity criteria for advancement, was selected for efficacy testing. The Thai “Phase III” trial, RV144, provided the first evidence that an HIV vaccine could provide protective efficacy (Rerks-Ngarm et al. 2009). The modified intent-to-treat analysis (excluding those randomized, but HIV-infected at the first vaccination visit) showed 31.2% efficacy (95% CI: 1.1,52.1; $p = 0.04$) after 42 months of follow-up after vaccination with AL VAC vCP1521 at 0, 1, 3, and 6 months with boosting with AIDSVAX B/E rgp120 at 3 and 6 months. Although not included in the prespecified analysis plan, vaccine efficacy appeared to be higher (60%, 95% CI 22,80) at 12 months postvaccination, suggesting an early, but nondurable, vaccine effect (Michael 2009). In a subset of HIV-negative volunteers who completed all immunizations, 20% had CD$^+$ ELISpot responses to Gag or Env. Intracellular cytokine staining showed predominantly CD4$^+$ responses favoring Env over Gag (34% vs. 1.4%). Lymphoproliferation to gp120 was approximately 87% for MN and 90% for A244. Few Nab were identified. ELISA binding against gp120 A244, gp120 MN, and p24 were positive in 98.6%, 98.6%, and 52.1% of vaccinees at 12 months, respectively. The most striking parallel to declining immunogenicity over time was a 10-fold drop in binding antibody to gp120 B and AE over the 6 months from the last vaccination.

**THE WAY FORWARD FROM RV144**
Identifying correlates of protection would revolutionize HIV-1 vaccine development. To this end, more than 30 investigators are collaborating to intensely characterize immune factors associated with vaccine efficacy (Kim et al. 2010). Studies include measures of Nab, ADCC, blocking of monoclonal antibody binding, immunoglobulin glycosylation and binding kinetics, phagocytosis, transcriptional profiling, immune phenotyping, and antigen specific cellular immune responses, cellular immunogenicity, host genetics testing, and other approaches to attempt to identify potential immune correlates or mechanisms of protection (Koup et al. 2010). Discovery of a correlate of protection from RV144 would provide a rational basis for further improvement of this regimen and newer vaccine approaches. In the absence of such a discovery, HIV vaccine development will have to build on RV144 in a more empirical fashion. This goal can be approached in two parallel, mutually supportive clinical development pathways (Fig. 1).

**Product Development Pathway**
This pathway takes the most direct extension from RV144, minimizes variable changes, and seeks the shortest pathway to licensure of a public health tool including the use of vaccines tailored for regional distribution of HIV subtypes in populations at highest risk for HIV infection. Because vaccine efficacy in RV144 appeared to wane from 60% at 12 months to 31% at 3.5 years, schedules incorporating booster doses will be evaluated in immunogenicity studies as a means to incrementally improve and sustain a vaccine efficacy $>50\%$ at 24 months. Efficacy studies are being discussed in populations at high risk of HIV infection including heterosexual,
Vector prime selection
- ALVAC is default
- RV144 immune correlates
- Immune grid
- Cost, product availability

Figure 1. Global clinical AIDS vaccine development. Depicted are three distinct, but interrelated, spheres of activity placed along a timeline. RV144 follow-up is ongoing, and seeks to identify a correlate of immune protection by interrogating RV144 samples or samples generated by follow-up studies. Exploratory research activities will include adaptive design clinical trials, which aim to rapidly identify next generation products that should proceed to efficacy testing. Product development activities seek to extend the RV144 proof of concept by studying pox-protein prime-boost strategies in high-risk populations from Africa and Thailand with different routes of exposure in pursuit of licensure to realize rapid public health benefit.

Sudani individuals in southern Africa and MSM in Thailand that could begin in 2014. These studies would build on RV144 by keeping vaccine constituents and schedule constant. Given that RV144 was conducted in a population at risk for primarily CRF01_AE infection, this variable would also be held constant in subsequent studies in Thailand. However, both the ALVAC inserts and the recombinant gp120 protein to be tested in southern Africa would need to be substituted with subtype C strains that match the prevalent regional circulating HIV variants. Any change in vaccine, population, or subtype will impact comparability of the studies. Finally, the gp120 recombinant protein boost for subsequent Thai and southern Africa studies has yet to be determined. This discussion is theoretically more straightforward for Thailand as AIDSVAX
B/E is the established precedent but is less intuitive for studies elsewhere.

Exploratory Research Pathway: Pox-Protein and Beyond

Parallel exploration of novel pox vectors and gp120 proteins/adjuvants to improve protective efficacy is warranted through iterative clinical research. Poxvirus vectors, such as NYVAC, merit consideration for research track exploration as they appear to generate greater cellular and humoral immune responses than ALVAC. Although the relevance of those evoked immune responses to protective efficacy is unknown, products that evoke qualitative and quantitative differences in immunogenicity compared to RV144 should be evaluated. The rgp120 used in RV144 was formulated with alum, a relatively weak adjuvant. Studies using more potent adjuvants such as MF59, are warranted as well as rgp120s that generate novel immunogenicity profiles in phase I clinical studies. The use of accelerated clinical study designs that efficiently eliminate poorly performing vaccine candidates should be part of this exploratory research pathway (Koup et al. 2010; Corey et al. 2011).

RV144 and the subsequent immunogenicity and efficacy studies that are being currently discussed are limited by the need the need to match HIV subtypes to specific regional epidemics. Increasing the valency of HIV vaccine candidates to capture a broader range of global HIV subtype diversity would provide the possibility of a globally effective preventive vaccine. Such an advance could enable a concerted HIV elimination strategy similar to the smallpox eradication campaign (Breman and Arita 1980). These factors have prompted development of strategies aimed at generating responses broad enough to afford vaccine recipients universal protection. One promising approach involves the use of polyvalent “mosaic” inserts which cover the range of HIV T-cell epitopes across HIV subtypes (Fischer et al. 2007; Abdulhaqq and Weiner 2008; Barouch et al. 2010). Replication-incompetent Ad26 vectored mosaic HIV-1 Gag, Pol, and Env antigens augmented breadth and depth of cellular immune responses in rhesus monkeys (Barouch et al. 2010), and both Ad26 and Ad35 vectored HIV-1 vaccine candidates, the former in combination with MVA mosaics are moving forward into phase I human clinical trials.

REFERENCES

*Reference is also in this collection.


Cite this article as Cold Spring Harb Perspect Med 2012;2:a007351
Human Vaccine Trials


R.J. O'Connell et al.


Cite this article as Cold Spring Harb Perspect Med 2012;2:a007351
R.J. O'Connell et al.


Human Vaccine Trials


# Human Immunodeficiency Virus Vaccine Trials

Robert J. O'Connell, Jerome H. Kim, Lawrence Corey and Nelson L. Michael

*Cold Spring Harb Perspect Med* 2012; doi: 10.1101/cshperspect.a007351

<table>
<thead>
<tr>
<th>Subject Collection</th>
<th>HIV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HIV Pathogenesis: Dynamics and Genetics of Viral Populations and Infected Cells</strong></td>
<td><strong>HIV-1 Pathogenesis: The Virus</strong></td>
</tr>
<tr>
<td>John Coffin and Ronald Swanstrom</td>
<td>Ronald Swanstrom and John Coffin</td>
</tr>
<tr>
<td><strong>Human Immunodeficiency Virus Vaccine Trials</strong></td>
<td><strong>The T-Cell Response to HIV</strong></td>
</tr>
<tr>
<td><strong>HIV Transmission</strong></td>
<td><strong>HIV-1 Reverse Transcription</strong></td>
</tr>
<tr>
<td>George M. Shaw and Eric Hunter</td>
<td>Wei-Shau Hu and Stephen H. Hughes</td>
</tr>
<tr>
<td><strong>Novel Cell and Gene Therapies for HIV</strong></td>
<td><strong>HIV Pathogenesis: The Host</strong></td>
</tr>
<tr>
<td>James A. Hoxie and Carl H. June</td>
<td>A.A. Lackner, Michael M. Lederman and Benigno Rodriguez</td>
</tr>
<tr>
<td><strong>Behavioral and Biomedical Combination Strategies for HIV Prevention</strong></td>
<td><strong>HIV: Cell Binding and Entry</strong></td>
</tr>
<tr>
<td>Linda-Gail Bekker, Chris Beyrer and Thomas C. Quinn</td>
<td>Craig B. Wilen, John C. Tilton and Robert W. Doms</td>
</tr>
<tr>
<td><strong>HIV-1 Assembly, Budding, and Maturation</strong></td>
<td><strong>Innate Immune Control of HIV</strong></td>
</tr>
<tr>
<td>Wesley I. Sundquist and Hans-Georg Kräusslich</td>
<td>Mary Carrington and Galit Alter</td>
</tr>
<tr>
<td><strong>HIV-1 Assembly, Budding, and Maturation</strong></td>
<td><strong>HIV DNA Integration</strong></td>
</tr>
<tr>
<td>Wesley I. Sundquist and Hans-Georg Kräusslich</td>
<td>Robert Craigie and Frederic D. Bushman</td>
</tr>
<tr>
<td><strong>Lessons in Nonhuman Primate Models for AIDS Vaccine Research: From Minefields to Milestones</strong></td>
<td><strong>HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment</strong></td>
</tr>
<tr>
<td>Jeffrey D. Lifson and Nancy L. Haigwood</td>
<td>Serena Spudich and Francisco González-Scarano</td>
</tr>
</tbody>
</table>

For additional articles in this collection, see [http://perspectivesinmedicine.cshlp.org/cgi/collection/](http://perspectivesinmedicine.cshlp.org/cgi/collection/)